Navigation Links
Genomic Health to Present at Bank of America Merrill Lynch Health Care Conference
Date:5/7/2013

REDWOOD CITY, Calif., May 7, 2013 /PRNewswire/ -- Genomic Health, Inc.  (Nasdaq: GHDX) today announced that members of its management team will present at the 2013 Bank of America Merrill Lynch Health Care Conference in Las Vegas on Tuesday, May 14 at 5:00 p.m. Pacific Time (PT). 

(Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO)

To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at http://investor.genomichealth.com.  Please connect to the website at least 15 minutes prior to the beginning of the presentation to allow for any necessary software downloads.  An archived replay will be available for three months beginning 24 hours after the live presentation.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions.  The company's lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS).  In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease.  As of March 31, 2013, more than 19,000 physicians in over 70 countries had ordered approximately 350,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit, www.GenomicHealth.com. To learn more about Oncotype DX tests, visit: www.OncotypeDX.com and www.mybreastcancertreatment.org

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the potential economic benefits associated with the company's tests; the ability of the company to develop additional tests in the future; the demand for the company's tests; the ability of any potential tests the company may develop to optimize cancer treatment and the Company's ability to launch new tests in new markets and expand internationally. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; unanticipated costs or delays in research and development efforts; our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the period ended March 31, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners. 


'/>"/>
SOURCE Genomic Health, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Real Time Genomics and Knome Ink Deal to Integrate and Sell the RTG Variant Platform on knoSYS100 System
2. Neogen launches comprehensive cattle genomic test
3. Real Time Genomics and J. Craig Venter Institute Embark on Strategic Research Initiative
4. Nimbix and Convey Partner for “The Accelerated Genomics Cloud” (TAGC) Promotion
5. Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories
6. Real Time Genomics and Omicia Partner on a Platform for Integrated Genomic Analysis for Childhood Disease
7. Venter Institute-Led Team Recovers and Sequences Genome of Periodontal Pathogen from Biofilm in Hospital Sink using Single-Cell Genomics
8. Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013
9. Squished bug genomics: Insect goo aids biodiversity research
10. Ingenuity Systems IPA Provides Researchers with Genomic Insights Suggesting that Physical Activity Does Not Slow Muscle Aging
11. BGI-Shenzhen Completes Acquisition of Complete Genomics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... ... announced the addition of Dr. Nancy Gillett to its Board of Directors. Dr. ... she served as Corporate Executive Vice President and Chief Scientific Officer. A board-certified ...
(Date:5/3/2016)... ... , ... According to world renowned prostate cancer surgeon, Dr. David B. ... two main treatment options: surgery or radiation. Based on a patient’s goals, disease state, ... enabled doctors to administer higher doses of radiation to prostate cancer patients ...
(Date:5/2/2016)... ... May 02, 2016 , ... F.E.E.D. Co., ... success of their revolutionary, veterinarian-designed product for indoor cats. The NoBowl Feeding System ... with their food the way nature intended. NoBowls make cats happy and healthy. ...
(Date:4/29/2016)... ... April 29, 2016 , ... During a two day program ... viable company, CereScan’s CEO, John Kelley, joined other Denver business leaders in providing ... in the Denver area business community, shared his top fundamental learnings in building ...
Breaking Biology Technology:
(Date:3/10/2016)... 10, 2016 --> ... report "Identity and Access Management Market by Component (Provisioning, ... Governance), by Organization Size, by Deployment, by Vertical, and ... MarketsandMarkets, The market is estimated to grow from USD ... 2020, at a Compound Annual Growth Rate (CAGR) of ...
(Date:3/9/2016)... 9, 2016 This BCC Research report provides ... the RNA Sequencing (RNA Seq) market for the years ... tools and reagents, data analysis, and services. ... the RNA-Sequencing market such as RNA-Sequencing tools and reagents, ... factors affecting each segment and forecast their market growth, ...
(Date:3/9/2016)... , March 9, 2016  Crossmatch ® ... and enrollment solutions, today announced the addition of ... Altus multi-factor authentication platform. New contextual ... managers to step-up security where it,s needed most ... Washington, DC . --> ...
Breaking Biology News(10 mins):